Structured evidence table for Saffron Cognitive Performance Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Saffron Cognitive Performance Randomized Trial | In recent years, a growing body of scientific evidence supporting several of these traditional uses has shown the potential of saffron and its main ingredients—crocins, crocetin, safranal, and picrocrocin—as pharmacologically relevant compounds. | 3 | Campos Catarina (2026) | From Stigma to Therapy: Pharmacological Insights into Saffron Bioactives for Major Non-Communicable Diseases |
| Saffron Cognitive Performance Randomized Trial | By integrating evidence from in vitro studies, animal models, and clinical trials, this review critically assesses saffron’s potential as a multi-target pharmacological agent and identifies key limitations and future directions for its development within pharmaceutical and integrative medicine frameworks. | 3 | Campos Catarina (2026) | From Stigma to Therapy: Pharmacological Insights into Saffron Bioactives for Major Non-Communicable Diseases |
| Saffron Cognitive Performance Randomized Trial | Considering the scope of disease areas covered, this review is intended to be a broad narrative overview rather than an exhaustive systematic evaluation of each disease, with a focus on critically evaluating study quality, level of evidence, gaps between preclinical findings and clinical applicability, and limitations across sections. | 3 | Campos Catarina (2026) | From Stigma to Therapy: Pharmacological Insights into Saffron Bioactives for Major Non-Communicable Diseases |
| Saffron Cognitive Performance Randomized Trial | Crocus sativus 1 2 3 4 5 6 Natural products remain one of the main sources of pharmacologically bioactive compounds (BACs) and have played a fundamental role in the development of new drugs. | 3 | Campos Catarina (2026) | From Stigma to Therapy: Pharmacological Insights into Saffron Bioactives for Major Non-Communicable Diseases |
| Saffron Cognitive Performance Randomized Trial | Advances in medicine, technology, and socioeconomic development have extended life expectancy, but these gains are accompanied by a steep rise in age-associated diseases (). | 4 | Li Lingyun (2025) | Integrative effects of saffron and physical activity on endurance performance, quality of life, cognitive, emotional, and metabolic outcomes in age-related and neurodegenerative diseases |
| Saffron Cognitive Performance Randomized Trial | These conditions are driven by a complex interplay of genetic, molecular, and environmental factors, with aging itself serving as the strongest risk factor (). | 4 | Li Lingyun (2025) | Integrative effects of saffron and physical activity on endurance performance, quality of life, cognitive, emotional, and metabolic outcomes in age-related and neurodegenerative diseases |
| Saffron Cognitive Performance Randomized Trial | These alterations ultimately compromise physiological resilience, leading to cognitive decline, emotional instability, impaired mobility, and increased vulnerability to chronic diseases. | 4 | Li Lingyun (2025) | Integrative effects of saffron and physical activity on endurance performance, quality of life, cognitive, emotional, and metabolic outcomes in age-related and neurodegenerative diseases |
| Saffron Cognitive Performance Randomized Trial | 1 2 3 The global demographic shift toward an increasingly older population has become one of the most pressing public health concerns of the current era. | 4 | Li Lingyun (2025) | Integrative effects of saffron and physical activity on endurance performance, quality of life, cognitive, emotional, and metabolic outcomes in age-related and neurodegenerative diseases |
Source documents